Company Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications.
In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis.
The company was incorporated in 2011 and is headquartered in Brisbane, California.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jul 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 71 |
| CEO | Douglas Love Esq., J.D. |
Contact Details
Address: 1400 Sierra Point Parkway, Bldg C, Suite 200 Brisbane, California 94005 United States | |
| Phone | (650)-822-5500 |
| Website | annexonbio.com |
Stock Details
| Ticker Symbol | ANNX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001528115 |
| CUSIP Number | 03589W102 |
| ISIN Number | US03589W1027 |
| Employer ID | 27-5414423 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Douglas Love Esq., J.D. | Chief Executive Officer, President and Director |
| Dr. Dean R. Artis Ph.D. | Chief Scientific Officer and Executive Vice President |
| Dr. Ted Yednock Ph.D. | Executive Vice President, Chief Innovation Officer and Chairman of the Scientific Advisory Board |
| Dr. Arnon Rosenthal Ph.D. | Founder |
| Jennifer Lew | Executive Vice President, Chief Financial Officer and Corporate Secretary |
| Michael Overdorf M.B.A. | Executive Vice President and Chief Business Officer |
| Henk-Andre Kroon M.D. | Senior Vice President of Translational Medicine |
| Dr. Jamie Dananberg M.D. | Executive Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 25, 2024 | ARS | Filing |
| Apr 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 5, 2024 | 424B5 | Filing |
| Apr 1, 2024 | EFFECT | Notice of Effectiveness |
| Mar 28, 2024 | UPLOAD | Filing |